Canonical text (the exact bytes fingerprinted)

TRUVACE RECORD VERSION
record: TRV-2026-2336
version: 1
kind: certified
reason: Certified into the record
timestamp: 2026-11-02T21:27:39.546643Z
status: published
lens: g_space
sector: health
headline: AI-Assisted Analysis of Clinical Trials to Identify Failed Drugs for Revival via Drug Delivery Technologies
dek: Numerous drug candidates showed great promise in experimental and preclinical investigations but failed in clinical trials. One cause to this problem may be nonspecific drug biodistribution, leading to adverse effects in healthy organs. Drug delivery technologies are developed to overcome this exact problem by navigating drugs more selectively to the disease sites. Therefore, they hold the promise to revive at least some failed drugs. However, it is challenging to identify such candidates revivable by drug deliv…
gain_title: An OpenAI-based framework classified terminated trials with 88.66% to 91.75% validation accuracy and flagged 817 trials possibly failed due to unwanted drug biodistribution, plus ten candidate small molecules.
problem_title: (none)
trace_subject: (none)
gain_reading: An OpenAI-based framework classified terminated trials with 88.66% to 91.75% validation accuracy and flagged 817 trials possibly failed due to unwanted drug biodistribution, plus ten candidate small molecules.
gain_evidence: which identified 817 trials possibly failed due to UB
problem_reading: (none)
problem_evidence: (none)
quick_read: Researchers built a framework on OpenAI models that reads terminated trial records on ClinicalTrials.gov. It extracts structured information, infers disease sites, and checks whether adverse effects appeared in different body locations than the targeted disease, a sign of unwanted drug distribution.

The work matters because failed trials are often described in unstructured, inconsistent language that is hard to survey manually. The approach could point developers toward drugs worth retesting with targeted delivery, but the study only flags candidates as possibly revivable and does not show that any drug has actually been revived.
limitation: The study addresses only the language problem; the lack of systematic patient biodistribution data remains unsolved, and the 817 trials are only possibly failed due to unwanted biodistribution.
tag: Evidence-backed gain
key_points: The framework analyzed terminated trials on ClinicalTrials.gov using structured extraction and disease-site inference. | Validation accuracy was 89.69% for unwanted-biodistribution failure, 91.75% for small molecule classification, and 88.66% for hydrophobicity. | Applied to all terminated trials, it identified 817 trials possibly failed due to unwanted biodistribution. | It also named the top ten small molecule drugs likely suited to the authors' peptide-guided delivery platform.
rundown: Many drug candidates look promising in preclinical work but fail in humans, partly because drugs spread nonspecifically and cause adverse effects in healthy organs. Delivery technologies aim to steer drugs to disease sites, so some failed drugs might be rescued.

Two obstacles make finding such candidates hard: patient biodistribution data are rarely collected systematically during trials, and failed-trial results are reported in unstructured or inconsistent language. The study addresses only the second problem using AI agents and large language models.

The screening also paired the failure classification with drug type and physicochemical properties such as molecular weight and hydrophobicity, and matched candidates to the authors' peptide-guided delivery platform.
sources:
- peer_reviewed | Molecular Pharmaceutics | https://doi.org/10.1021/acs.molpharmaceut.6c00594 | 2026-11-02
prev: 0000000000000000000000000000000000000000000000000000000000000000

sha256

4971dcfad108c4a81a42689ef58728930505078e526f1f94bbbe35429d3429ab

previous

0000000000000000000000000000000000000000000000000000000000000000